GE HealthCare Snags Sofie Biosciences in $945M Deal
GE HealthCare is acquiring Sofie Biosciences for $945M, bolstering its nuclear medicine and PET imaging portfolio.
GE HealthCare is writing a $945 million check for Sofie Biosciences, and this deal tells you exactly where the smart money in med-tech is flowing right now — radiopharmaceuticals and PET imaging. If you're holding GEHC, pay attention.
Sofie Biosciences brings specialized expertise in molecular imaging agents, the kind of diagnostic tools that are becoming indispensable as precision medicine scales up. Nuclear medicine is no longer a niche corner of healthcare — it's a growth engine, and GE HealthCare is making sure it owns a bigger piece of it.
Read more Modern Treasury Pursues Federal Trust Bank Charter for Crypto Custody →
The $945 million price tag is a bold move for a company that's been deliberately expanding its diagnostics footprint since spinning off from GE in 2023. This acquisition signals that management isn't done reshaping the portfolio. You don't drop nearly a billion dollars on a target unless you see a clear revenue runway ahead.
For traders and investors, the strategic logic is straightforward: demand for advanced imaging — especially PET scans tied to oncology and neurology diagnostics — is accelerating. GE HealthCare is essentially buying into that secular tailwind. Watch how the Street prices in the deal's impact on forward earnings multiples over the next few sessions.
Continue reading at SeekingAlpha.
